Home-use brain stimulation (tDCS) for chronic neuropathic or nociplastic pain
Official title: Efficacy of Home-delivered Transcranial Direct Current Stimulation (tDCS) of the Motor Cortex in Patients With Chronic Pain Transiently Relieved by Motor Cortex rTMS : a Pragmatic Randomized Double Blind Sham Controlled Trial
Run by Hospital Ambroise Paré Paris · NCT07211256 · Data updated 2026-11-12
This trial will test whether using a home tDCS device for 12 weeks can reduce pain in people with chronic neuropathic or nociplastic pain who had only short-term relief from rTMS.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Hospital Ambroise Paré Paris Academic / other |
| Locations | 1 site (Boulogne-Billancourt, Hauts de Seine) |
| Status | Recruiting |
| Started | January 9, 2025 |
| Main results expected | February 2028 |
| Study ends | February 2028 |
| Registry record updated | October 7, 2025 |
| Trial ID | NCT07211256 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with chronic (≥6 months) neuropathic or nociplastic pain who had at least 30% but short-lived (<1 month) pain relief after motor-cortex rTMS and who can use a home device are ideal candidates.
✕Probably not a fit
Patients with contraindications to tDCS (implantable devices, epilepsy, severe cognitive or skin conditions), on high-risk medications, or those unlikely to tolerate the device are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, double-blind, placebo-controlled, two-center trial comparing active versus sham transcranial direct current stimulation (tDCS) delivered at home. Eligible participants previously experienced at least 30% pain relief from motor-cortex rTMS but lost that benefit within one month and will stop rTMS for at least one month before enrollment. Participants will perform 20-minute tDCS sessions (2 mA) at home five days per week for 12 weeks, with monthly assessments of pain intensity and secondary outcomes such as quality of life, sleep, mood, and global impression of change. Safety is monitored at each follow-up and a blinded interim analysis in the first 40 patients may stop the trial early for futility or safety concerns.
Why it matters
Potential benefit: If successful, home tDCS could provide a convenient way to extend or restore pain relief without repeated hospital rTMS visits.
How similar studies have gone: Prior randomized trials and meta-analyses show modest and mixed benefits of tDCS for chronic pain, but home-delivered tDCS, particularly in patients selected after rTMS, remains relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Chronic pain for at least 6 months Pain intensity ≥ 4/10 on 0-10 NRS Pain present every day or nearly every day Neuropathic pain (DN4 score ≥ 4/10) or nociplastic pain (Kosek et al Pain 2021) Patients previously treated with rTMS of the motor cortex in routine in our pain center but with only transient efficacy (ie, efficacy for less than one month, defined as pain intensity improved by at least 30 %) Affilitated to social security Exclusion Criteria: Contraindications to tDCS as stated in the manufacturer brochure (ie, implantable device , severe cognitive disorders, epilepsia, skin problems where will placed the electrodes, arterial or venous thrombosis, thrombophlebitis, metallic intracranial implant, cranioth-omy, incracranial aneuvrysm, cerebral tumor, severel sleep disorders such as narcolepsia) Conciomitant treatment which might increase the risk of epilepsia such as high doses opioids (≥ 140 mg morphine equivalent) or high. doses tricyclic antidepressants (≥ 150 mg per day) Pregnancy or lactation Age below 18 or \> 80 years Pending litigation related to pain Pain more severe than neuropathic or nociplastic pain requiring treatment Severe disease such as cancer Severe psychiatric condition (psychosis) Impossible to be followed for up to 3 months Participation in a recent protocol (less than 3 months) Psychoactive drug abuse
Where it's running
-
Centre d'Evaluation et de Traitement de la douleur, INSERM U 987
Boulogne-Billancourt, Hauts de Seine, France Recruiting
Study contacts
- Study coordinator: Nadine ATTAL, MD PhD
- Email: nadine.attal@aphp.fr
- Phone: 0033149095931
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing different NSAIDs plus home exercises for frozen shoulder
This will test whether taking one of several NSAIDs (diclofenac, meloxicam, or indomethacin) together with home shoulder exercises helps adults aged 18–75 with frozen shoulder and whether pain type changes the benefit.
-
Ultrasound-guided shoulder injections for frozen shoulder
This tests whether adding ultrasound-guided suprascapular nerve block, with or without a subacromial injection, to a home exercise program reduces pain and improves shoulder function in adults with chronic frozen shoulder.
-
Neuropathic Pain Severity in Lumbar Spinal Stenosis and Its Link to Radiology
This study will test how severe neuropathic pain is in adults with lumbar spinal stenosis and see if it relates to MRI findings and other clinical features.
-
Virtual Reality-Based Hypnotherapy to Help Pain, Sleep, and Mood in Spinal Cord Injury
Adults with spinal cord injury will try adding short VR-based hypnotherapy sessions to their standard physiotherapy to see if it reduces pain and improves sleep and mood.
-
Extended-release Pregabalin for nerve pain from diabetes or shingles
This phase 3 study tests an extended-release form of pregabalin to see if it reduces nerve-pain symptoms in adults with diabetic neuropathy or postherpetic neuralgia.
-
High-Intensity Peripheral Magnetic Stimulation for Traumatic Nerve Injury
This study tests whether adding high-intensity peripheral magnetic stimulation to a structured exercise program can reduce pain and improve function for adults with a traumatic peripheral nerve injury.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.